Aktualne i nowe strategie leczenia aktywnej orbitopatii tarczycowej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2020
Słowa kluczowe:
oftalmopatia Gravesa, nadczynność tarczycy, autoimmunogenność, immunosupresja, glikokortykosteroidy, radioterapia, przeciwciała monoklonalne
##plugins.themes.bootstrap3.article.main##
Abstrakt
Orbitopatia tarczycowa, zwana także oftalmopatią Gravesa, jest następstwem reakcji autoimmunologicznej w oczodole wywołanej przez wspólny dla tarczycy i oczodołu antygen lub antygeny. W niniejszym artykule na podstawie koncepcji patogenezy orbitopatii tarczycowej omówiono aktualną strategię oraz nowe kierunki leczenia zarówno hipertyreozy, jak i aktywnej fazy oftalmopatii. Tradycyjna strategia leczenia orbitopatii obejmuje leczenie immunosupresyjne za pomocą glikokortykosteroidów, radioterapię oczodołów i dekompresję chirurgiczną. Nowe kierunki terapii związane są z zastosowaniem leków specyficznie modulujących określone białka komórkowe zaangażowane w szlaki reakcji autoimmunologicznej w oczodole. Należą do nich przeciwciała monoklonalne, inhibitory cytokin oraz selektywne związki immunosupresyjne.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Wierzbowska J. Aktualne i nowe strategie leczenia aktywnej orbitopatii tarczycowej. Ophthatherapy [Internet]. 30 czerwiec 2020 [cytowane 22 listopad 2024];7(2):108-15. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1038
Numer
Dział
Terapie zachowawcze
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Tanda ML, Piantanida E, Liparulo L et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. Clin Endocrinol Metab. 2013; 98: 1443-9. https://doi.org/10.1210/jc.2012-3873.
2. Hiromatsu Y, Eguchi H, Tani J et al. Graves' ophthalmopathy: epidemiology and natural history. Intern Med. 2014; 53: 353-60.
3. Sawicka-Gutaj N, Gutaj P, Sowiński J et al. Influence of cigarette smoking on thyroid gland-an update. Endokrynol Pol. 2014; 65: 54-62. https://doi.org/10.5603/EP.2014.0008.
4. Wiersinga WM. Graves’ ophthalmopathy. Thyroid International 1997; 3: 1-15.
5. Blandford AD, Zhang D, Chundury RV et al. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol. 2017; 12: 111-21. https://doi.org/10.1080/17469899.2017.1276444.
6. Heufelder AE, Dutton CM, Sarkar G et al. Detection of TSH receptor mRNA in cultured fibroblasts from patients with Graves’ ophthalmopathy and pretibial dermopathy. Thyroid 1993; 3: 297-300.
7. Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014; 55: 1735-48.
8. Yeatts RP. Graves’ ophthalmopathy. Med Clin North Am. 1995; 79: 195-209.
9. Donaldson SS, Bagshaw MA, Kriss P. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1973; 37: 276-85.
10. Mourits MP, Koorneef L, Wiersinga WM et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989; 73: 639-44.
11. Gerding MN, van der Meer JWC, Broenink M et al. Association of thyrotropin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol. 2000; 52: 267-71.
12. Drui D, Du Pasquier Fediaevski L, Vignal Clermont C et al. Graves' orbitopathy: Diagnosis and treatment. Ann Endocrinol (Paris). 2018; 79: 656-64. https://doi.org/10.1016/j.ando.2018.08.005.
13. Ruchała M, Sawicka-Gutaj N. Advances in the pharmacological treatment of Graves' orbitopathy. Expert Rev Clin Pharmacol. 2016; 9: 981-9. https://doi.org/:10.1586/17512433.2016.1165606.
14. Bartalena L, Baldeschi L, Dickinson A et al. European Group on Graves' Orbitopathy (EUGOGO) Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO, Eur J Endocrinol. 2008; 158(3): 273-85.
15. Shiber S, Stiebel-Kalish H, Shimon I et al. Glucocorticoid regimens for prevention of Graves' ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid. 2014; 24: 1515-23. https://doi.org/10.1089/thy.2014.0218.
16. Kotwal A, Stan M. Current and Future Treatments for Graves' Disease and Graves' Ophthalmopathy. Horm Metab Res. 2018; 50: 871-86. https://doi.org/10.1055/a-0739-8134.
17. Miśkiewicz P, Kryczka A, Ambroziak U et al. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe? Endokrynol Pol. 2014; 65(5): 402-13. https://doi.org/10.5603/EP.2014.0056.
18. Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011; 96: 320-32. https://doi.org/10.1210/jc.2010-1962.
19. Bartalena L, Marcocci C, Chiovato L et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparision with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983; 56(6): 1139-44.
20. Stan MN, Garrity JA, Bradley EA et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab. 2006; 91: 4817-24.
21. Świerkot M, Kulawik G, Sarnat-Kucharczyk M et al. Long-term remission of steroid-resistant Graves' orbitopathy after administration of anti-thymocyte globulin. Endokrynol Pol. 2020; 71(2): 198-9. https://doi.org/10.5603/EP.a2019.0067.
22. Stan MN, Garrity JA, Carranza Leon BG et al. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab. 2015; 100(2): 432-41. https://doi.org/10.1210/jc.2014-2572.
23. Salvi M, Vannucchi G, Currò N et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015; 100: 422-31. https://doi.org/10.1210/jc.2014-3014.
24. Pérez-Moreiras JV, Alvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant graves' orbitopathy. Ophthalmic Plast Reconstr Surg. 2014; 30: 162-7. https://doi.org/10.1097/IOP.0000000000000037.
25. Pascual-Camps I, Molina-Pallete R, Bort-Martí MA et al. Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy. Orbit. 2018; 37: 450-3. https://doi.org/10.1080/01676830.2018.1435694.
26. Smith TJ, Kahaly GJ, Ezra DG et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017; 376: 1748-61. https:// doi.org/10.1056/NEJMoa1614949.
27. Krieger CC, Place RF, Bevilacqua C et al. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis. J Clin Endocrinol Metab. 2016; 101: 2340-7. https://doi.org/10.1210/jc.2016-1315.
28. Paridaens D, van den Bosch WA, van der Loos TL et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye (Lond). 2005; 19: 1286-9.
29. Ye X, Bo X, Hu X et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy. Clin Endocrinol (Oxf). 2017; 86: 247-55. https://doi.org/10.1111/cen.13170.
30. Kahaly GJ, Riedl M, König J et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate- to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018; 6: 287-98. https://doi.org/10.1016/S2213-8587(18)30020-2.
2. Hiromatsu Y, Eguchi H, Tani J et al. Graves' ophthalmopathy: epidemiology and natural history. Intern Med. 2014; 53: 353-60.
3. Sawicka-Gutaj N, Gutaj P, Sowiński J et al. Influence of cigarette smoking on thyroid gland-an update. Endokrynol Pol. 2014; 65: 54-62. https://doi.org/10.5603/EP.2014.0008.
4. Wiersinga WM. Graves’ ophthalmopathy. Thyroid International 1997; 3: 1-15.
5. Blandford AD, Zhang D, Chundury RV et al. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol. 2017; 12: 111-21. https://doi.org/10.1080/17469899.2017.1276444.
6. Heufelder AE, Dutton CM, Sarkar G et al. Detection of TSH receptor mRNA in cultured fibroblasts from patients with Graves’ ophthalmopathy and pretibial dermopathy. Thyroid 1993; 3: 297-300.
7. Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014; 55: 1735-48.
8. Yeatts RP. Graves’ ophthalmopathy. Med Clin North Am. 1995; 79: 195-209.
9. Donaldson SS, Bagshaw MA, Kriss P. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1973; 37: 276-85.
10. Mourits MP, Koorneef L, Wiersinga WM et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989; 73: 639-44.
11. Gerding MN, van der Meer JWC, Broenink M et al. Association of thyrotropin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol. 2000; 52: 267-71.
12. Drui D, Du Pasquier Fediaevski L, Vignal Clermont C et al. Graves' orbitopathy: Diagnosis and treatment. Ann Endocrinol (Paris). 2018; 79: 656-64. https://doi.org/10.1016/j.ando.2018.08.005.
13. Ruchała M, Sawicka-Gutaj N. Advances in the pharmacological treatment of Graves' orbitopathy. Expert Rev Clin Pharmacol. 2016; 9: 981-9. https://doi.org/:10.1586/17512433.2016.1165606.
14. Bartalena L, Baldeschi L, Dickinson A et al. European Group on Graves' Orbitopathy (EUGOGO) Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO, Eur J Endocrinol. 2008; 158(3): 273-85.
15. Shiber S, Stiebel-Kalish H, Shimon I et al. Glucocorticoid regimens for prevention of Graves' ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid. 2014; 24: 1515-23. https://doi.org/10.1089/thy.2014.0218.
16. Kotwal A, Stan M. Current and Future Treatments for Graves' Disease and Graves' Ophthalmopathy. Horm Metab Res. 2018; 50: 871-86. https://doi.org/10.1055/a-0739-8134.
17. Miśkiewicz P, Kryczka A, Ambroziak U et al. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe? Endokrynol Pol. 2014; 65(5): 402-13. https://doi.org/10.5603/EP.2014.0056.
18. Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011; 96: 320-32. https://doi.org/10.1210/jc.2010-1962.
19. Bartalena L, Marcocci C, Chiovato L et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparision with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983; 56(6): 1139-44.
20. Stan MN, Garrity JA, Bradley EA et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab. 2006; 91: 4817-24.
21. Świerkot M, Kulawik G, Sarnat-Kucharczyk M et al. Long-term remission of steroid-resistant Graves' orbitopathy after administration of anti-thymocyte globulin. Endokrynol Pol. 2020; 71(2): 198-9. https://doi.org/10.5603/EP.a2019.0067.
22. Stan MN, Garrity JA, Carranza Leon BG et al. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab. 2015; 100(2): 432-41. https://doi.org/10.1210/jc.2014-2572.
23. Salvi M, Vannucchi G, Currò N et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015; 100: 422-31. https://doi.org/10.1210/jc.2014-3014.
24. Pérez-Moreiras JV, Alvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant graves' orbitopathy. Ophthalmic Plast Reconstr Surg. 2014; 30: 162-7. https://doi.org/10.1097/IOP.0000000000000037.
25. Pascual-Camps I, Molina-Pallete R, Bort-Martí MA et al. Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy. Orbit. 2018; 37: 450-3. https://doi.org/10.1080/01676830.2018.1435694.
26. Smith TJ, Kahaly GJ, Ezra DG et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017; 376: 1748-61. https:// doi.org/10.1056/NEJMoa1614949.
27. Krieger CC, Place RF, Bevilacqua C et al. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis. J Clin Endocrinol Metab. 2016; 101: 2340-7. https://doi.org/10.1210/jc.2016-1315.
28. Paridaens D, van den Bosch WA, van der Loos TL et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye (Lond). 2005; 19: 1286-9.
29. Ye X, Bo X, Hu X et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy. Clin Endocrinol (Oxf). 2017; 86: 247-55. https://doi.org/10.1111/cen.13170.
30. Kahaly GJ, Riedl M, König J et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate- to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018; 6: 287-98. https://doi.org/10.1016/S2213-8587(18)30020-2.